Dr Agarwal Healthcare IPO allotment status will be finalized on February 3. Investors can check their status on Kfin ...

By Rishika Sadam HYDERABAD (Reuters) -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its ...

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new ...

Nirmala Sitharaman is set to present the first full Budget of Modi 3.0, balancing tax cut hopes and growth needs. With GDP ...